Crescent Biopharma Expands Oncology Trial Cohorts
The company is enrolling patients in chemotherapy combination studies for its lead cancer drug candidate.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Is the current pace of bringing new experimental cancer therapies to clinical trials sufficient?
Crescent Biopharma has begun enrolling patients into new chemotherapy combination cohorts as part of its ongoing Phase 1/2 ASCEND clinical trial. These expansion efforts aim to evaluate the efficacy of the drug CR-001 as a treatment for various solid tumor types.
Why it matters
By integrating CR-001 with standard chemotherapy regimens, the trial seeks to broaden the potential therapeutic applications of the antibody-drug conjugate. Successful results in these cohorts could provide a critical pathway for treating aggressive cancers that remain resistant to traditional therapies.
Crescent Biopharma has dosed 125 patients in the ASCEND trial across the United States, Europe, and South Korea. The company has secured seven total IND clearances and aims to have 2,000 patients dosed across its entire portfolio by mid-2027.
The players
Crescent Biopharma
A biopharmaceutical company headquartered in Waltham, Massachusetts, that focuses on the development of novel antibody-drug conjugates for cancer treatment.
Kelun-Biotech
A biotechnology firm that holds exclusive rights to the drug candidate CR-001 in Greater China and is partnering on global clinical development.
The details
The firm is conducting these studies in collaboration with Kelun-Biotech, focusing on combinations involving sacituzumab tirumotecan and CR-001. In addition to these efforts, the company recently received IND clearance from the U.S. Food and Drug Administration for its second candidate, CR-002.
Timeline
Initial monotherapy data from the ASCEND trial is expected in Q1 2027.
Data from chemotherapy combination cohorts is anticipated by mid-2027.
Initial data for the drug candidate CR-002 is expected in the second half of 2027.
The initiation of Phase 3 studies for CR-001 is planned for early 2028.
Health Landscape
The expansion of these combination trials follows the broader industry trend of accelerating the development of antibody-drug conjugates for solid tumors. This approach reflects an ongoing shift in oncology toward multi-modal therapies designed to improve patient response rates.
Patients currently managing solid tumors may gain access to emerging treatment options as these combination trials progress. The results of these studies will eventually determine if this specific chemotherapy pairing becomes a viable new standard for clinical care.
The takeaway
Clinical trials for new oncology drugs often require years of staged data reporting to establish both safety and efficacy. Patients and families tracking these advancements should look for subsequent Phase 3 milestone updates beginning in 2028.
Further reading
For more on current oncology research, see the latest developments in Cancer.
Live Poll
Is the current pace of bringing new experimental cancer therapies to clinical trials sufficient?
